Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis

被引：0
|
作者：
Duparc, Helene
Muller, Delphine
Antony-Debre, Ileana
Marty, Caroline
Debili, Najet
Villeval, Jean-Luc
Plo, Isabelle
Vainchenker, William
Gilles, Laure
Raslova, Hana
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141092
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] CDK4/6 inhibitors
    不详
    CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
  • [32] CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
    Yi-Bo Hou
    Kunmei Ji
    Yue-Tong Sun
    Li-Na Zhang
    Jia-Jie Chen
    Journal of Translational Medicine, 17
  • [33] CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
    Eggersmann, Tanja K.
    Degenhardt, Tom
    Gluz, Oleg
    Wuerstlein, Rachel
    Harbeck, Nadia
    BIODRUGS, 2019, 33 (02) : 125 - 135
  • [34] Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib
    Bouchekioua-Bouzaghou, Katia
    Lenihan, Catherine
    Shia, Alice
    Wilkes, Edmund
    Casado-Izquierdo, Pedro
    Cutillas, Pedro
    Schmid, Peter
    CANCER RESEARCH, 2016, 76
  • [35] Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib
    Costa, R.
    Costa, R. B.
    Talamantes, Sarah M.
    Helenowski, Irene
    Peterson, Jonna
    Kaplan, Jason
    Carneiro, B. A.
    Giles, Francis J.
    Gradishar, W. J.
    BREAST, 2017, 35 : 1 - 7
  • [36] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [37] Optimizing the combination of the CDK4/6 inhibitor palbociclib and paclitaxel using cell cycle analysis
    Spencer, Jade A.
    Race, Amanda D.
    Cooper, Patricia A.
    Shnyder, Steven D.
    Loadman, Paul M.
    Twelves, Christopher J.
    CANCER RESEARCH, 2020, 80 (16)
  • [38] CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
    Tanja K. Eggersmann
    Tom Degenhardt
    Oleg Gluz
    Rachel Wuerstlein
    Nadia Harbeck
    BioDrugs, 2019, 33 : 125 - 135
  • [39] Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
    Jin, Dan
    Nguyen Tran
    Thomas, Nagheme
    Tran, David D.
    PLOS ONE, 2019, 14 (10):
  • [40] CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
    Hou, Yi-Bo
    Ji, Kunmei
    Sun, Yue-Tong
    Zhang, Li-Na
    Chen, Jia-Jie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
12345